Long before 4-Aza-5Alpha-Androsta-1-En-3-One-17Beta-Carboxylic Acid entered any research catalog, chemists explored steroidal frameworks to understand hormone pathways and cellular signals. The molecule’s foundation comes from decades of trial, error, and serendipitous discoveries with androstane-based scaffolds. Researchers in the mid-20th century noticed how small tweaks in the steroid core could change activity, sparking curiosity around “aza” analogues—these swap a carbon atom for nitrogen within the ring. As years rolled on, analytical techniques matured. Scientists could confirm structure by nuclear magnetic resonance and fine-tune syntheses down to precise atom placement. At the turn of our century, this acid grabbed special notice in labs focused on endocrine disruption and enzyme inhibition. Its history ties tightly to advances in chemical synthesis and hormone biology.
Reaching far beyond pharma textbooks, 4-Aza-5Alpha-Androsta-1-En-3-One-17Beta-Carboxylic Acid sits at the crossroads of chemical research and therapeutic exploration. People in medicinal chemistry labs ask it tough questions about enzyme pathways and receptor binding. This molecule, often shipped as a white powder, cuts to the core of many studies in inhibitors—especially those probing the mystery of 5-alpha reductase and related enzymes. With interest growing in hormone-based disease, this acid isn’t tucked away in obscurity; it’s on the bench-top as both a reference standard and an experimental probe.
At room temperature, this substance won’t grab anyone’s eye with bright colors—it appears as a fine, odorless white powder. Water keeps it at arm’s length, but organic solvents like ethanol or dimethyl sulfoxide break it down for study. Heat doesn’t treat it kindly; above 200 degrees Celsius, this molecule will start to crack apart. Its chemical structure carries the signature shape of a steroid backbone, but with a twist: nitrogen blends into the ring, while a sharp carboxylic acid group juts out at carbon-17. Hydrogen, oxygen, carbon, and nitrogen each play a role, stacking up to a formula that points back to its roots in androstane chemistry. Stability under standard lab conditions lets researchers store it without worry, but it’s not something anyone tosses into the open air—it deserves careful handling.
Product labels make no room for fluff: purity checks in above 97% nearly every time. It comes measured by precise mass, bagged tight to keep out light and air. Each container lists the lot number, date of synthesis, and basic physical details such as melting point and solubility range. Many suppliers flash a CAS number and molecular formula on every document, so researchers can cross-check before popping the seal. SDS sheets walk through all hazards and storage tips. Proper labeling isn’t just paperwork—regulatory agencies demand it for tracking and compliance, whether the molecule’s heading to a biotech start-up or a university core lab.
Building this complex acid doesn’t happen overnight. Most synthetic routes trace their beginnings to an androstane base, often starting with androst-4-ene-3,17-dione or related chemicals easily bought or isolated. Chemists move stepwise through oxidation, nitration, and ring-closure. The “aza” piece comes from smart nitrogen insertion, using reagents like hydrazine and catalyzed under controlled pH. Carboxylation near the end seals the molecule’s fate, locking down that tell-tale 17-beta acid group. Each batch must run through columns or crystallization for purity, and the process ties up equipment for days, if not longer. I once watched an experienced team run this synthesis—patience, sharp eyes, and steady hands matter more than any robotic set-up.
Once the base molecule is in hand, chemists love to prod it with all kinds of reagents. Reduction at the nine-position, methylation along the ring, or esterification of the carboxyl can all shift its behavior. Some labs try halogenation at open positions to bump up biological activity or change water solubility. By tweaking here and there, teams get a clear sense of what features attract enzymes or fend off unwanted reactions in the body. Most of these changes start with easy-to-get reagents, but managing selectivity isn’t child’s play—off-target changes can waste days of work. At every modification, the goal stays steady: unlock a new property or deepen insight into how the molecule’s backbone talks with proteins, enzymes, or even cell membranes.
People rarely see this molecule named just one way. One catalog calls it “Finasteride Acid,” another “17β-Carboxylic Acid-4-Aza-5α-androsta-1-en-3-one.” Chemical abstracts might list a long systematic name, while some drug development books keep things shorter. Over time, researchers get used to shorthand: 4-aza for the nitrogen tweak, androsta for the ring, and 17β-carboxylic signposting that tail end acid group. This tangle of synonyms keeps everyone scanning product inserts before ordering or starting up an experiment, because one slip in nomenclature can send a study spinning the wrong direction.
Sharpening safety habits is non-negotiable for handling this compound. Gloves and lab coats aren’t enough: goggles block accidental splashes, and fume hoods draw away any vapor. Even though it doesn’t burn or release volatile hazards under most storage, mixing it with reactive chemicals needs extra care. Material Safety Data Sheets (MSDS) spell out not just fire risks but also signs of overexposure, including skin and respiratory reactions. Teams writing Standard Operating Procedures (SOPs) check current regulations, lock up stock bottles, and keep detailed logs of use. Auditors from both inside organizations and outside agencies track every transfer to make sure nobody bends the rules. I’ve watched entire research projects grind to a halt over a missing log entry—no one takes short cuts when safety regulators watch.
Most research hits center around blocking enzymes or mapping hormone pathways. Pharmaceutical scouts test it for effect on DHT production—a major target for prostate and hair disorders. In enzyme assays, it maps out pathways with sharper results than older reference chemicals. Its carboxylic acid moiety gets explored for prodrug strategies, studying how to mask activity or target specific tissues. Research stretching beyond medical frontiers investigates environmental breakdown in soil and water systems, since steroid analogues sometimes leach out of therapeutic waste. Only a handful of university teams pivot to exploring agricultural or veterinary uses, but the groundwork for crop and animal research keeps broadening each year. Wherever the bench or field takes it, this molecule attracts as many biologists and toxicologists as it does organic chemists.
Over the last decade, funding for modifying this steroidal acid has sparked fresh ideas about enzyme inhibitors and targeted therapies. Each grant cycle stacks new results: some teams probe cell cultures, mapping how slight changes slash enzyme function; others push into animal models, tracking effects on hormone cascades and disease progression. Computer modeling now partners with wet-bench efforts, shaving months off trial-and-error cycles. Databases balloon with analogues, and peer-reviewed journals flow with structural activity relationships. Not every lead pans out, but a few analogues with this backbone weave into updated treatments for hormone-linked cancers and hyperplastic states. Tracking patent filings shows that corporations plus academic labs see the promise and are willing to invest big. My years in the field taught me: behind ultra-specific syntheses and pages of spectral data are real patients, real needs, and a strong push to outpace current therapies.
Raising the bar on safety, toxicology teams dig deep. Standard screens look at both acute and chronic exposure: cell viability, organ function, genotoxicity, and environmental impact. While metabolism in animal models charts possible buildup or breakdown issues, in vitro studies probe any DNA or protein changes after exposure. Findings point to relatively manageable risk in controlled lab settings, but caution lingers: steroidal analogues, given at high doses or over long periods, can build up or disrupt hormonal axes in unexpected ways. Some teams probe reproductive effects, others test for allergenic responses among those handling the compound daily. Environmental toxicologists chart how derivatives drift through soil and water, looking for potential contamination. Data from animals and cell culture don’t always predict human outcomes, pushing for long-term surveillance wherever clinical use seems likely.
Fresh interest in hormone disorders and targeted oncology therapies keeps research alive and kicking. Big pharmaceutical houses and nimble start-ups alike search for sharper enzyme blockers and molecules with fewer side effects. Advances in green chemistry may cut down synthetic waste or push for biocatalytic routes, making these acids more sustainable. As personalized medicine picks up speed, analogues with the 4-aza-androsta core could anchor tailored treatments for genetic subtypes of cancer or endocrine disease. Orphan indications—rare hormonal imbalances—might see tailored drugs where broad-spectrum treatments once ruled. Data science, particularly with AI review of structure-activity landscapes, could uncover untapped synthetic routes or unexpected biological targets. With each step, collaboration between chemists, clinicians, and regulatory agencies aims to unlock benefits, guarding safety and reducing ecological footprint along the way.
4-Aza-5Alpha-Androsta-1-En-3-One-17Beta-Carboxylic Acid grabs attention mostly in the world of medical research and drug development. Its chemical structure connects it to the family of steroids, yet it’s not your average hormone or gym supplement. Scientists have their eyes on this compound for what it can do to disrupt the process that causes certain diseases.
Some time back, I watched a group of endocrinologists debate the stubborn challenge of treating prostate issues and hormone-driven cancers. Drugs that block DHT (dihydrotestosterone), a potent male hormone, made a clear difference in these diseases. Here’s the thing: 4-Aza-5Alpha-Androsta-1-En-3-One-17Beta-Carboxylic Acid functions as a 5α-reductase inhibitor. That means it can interfere with the body’s ability to convert testosterone into DHT. By limiting this hormone, the compound has shown promise in curbing the growth of prostate tissue in animal models. This opens up better options for managing conditions like benign prostatic hyperplasia (BPH) and, sometimes, prostate cancer.
The journey from theory to bedside takes patience. Before any doctor writes it on a prescription pad, researchers need to understand how it interacts with the body. Animal studies give insights, but people want to see strong evidence from well-run clinical trials. There’s excitement bubbling in labs because other 5α-reductase inhibitors like finasteride or dutasteride have set a solid precedent. They marked a shift for patients who live in discomfort from prostate swelling or hair loss driven by hormones. 4-Aza-5Alpha-Androsta-1-En-3-One-17Beta-Carboxylic Acid hints at a possibility of new drugs with fewer side effects or better results.
Drug development rarely follows a straight path. Every promising candidate brings hope but also raises questions about long-term safety and unexpected reactions in people. Some drugs block a necessary enzyme a bit too well, sabotaging hormone balance and nudging patients into a new set of problems. With this compound, researchers have a hint of optimism because of its specificity. Focusing on targeted inhibition might prevent the common muscle loss and sexual side effects that plague older drugs in the same category.
Cost is another piece of the puzzle. Making a new drug isn’t cheap. Finding a way to synthesize it reliably for commercial use could mean affordable treatment for millions of men as they age. Pharmaceutical companies often pass on these savings or costs to patients, so better efficiency in the lab translates to better access in the pharmacy.
No single discovery changes medicine overnight, but building blocks like 4-Aza-5Alpha-Androsta-1-En-3-One-17Beta-Carboxylic Acid matter for the bigger picture. Doctors and patients benefit when drug options expand, especially with conditions that chip away at quality of life. Responsible research—transparent trials, serious monitoring of adverse effects, and fair pricing—keeps things fair for everyone involved. Drug innovation feels slow, but every small step makes the treatment landscape stronger, offering hope to people who need it most.
Ask a pharmacist about 4-Aza-5Alpha-Androsta-1-En-3-One-17Beta-Carboxylic Acid, and you'll probably get a raised eyebrow. You’ll mostly find this chemical in labs, not in regular medicine cabinets. Chemists and hormone researchers look at this compound because it blocks certain enzymes in the body’s steroid pathways. The question of safety comes up among athletes, supplement fans, and curious onlookers whenever a new "cutting edge" substance pops up.
Long names don’t make things automatically dangerous, but this isn’t something you want to take lightly. Few peer-reviewed articles dig into its effects on people outside lab animals. Known relatives, like finasteride and dutasteride, treat hair loss and prostate issues but come with their own baggage—mood changes, hormone swings, and sometimes sexual side effects. Those drugs went through years of trials and strict approval processes. Meanwhile, this newer synthetic cousin hasn’t earned that kind of attention on the safety front.
I’ve worked behind the counter at a pharmacy. I’ve seen plenty of trends where folks jump to try a compound they don't know much about. Sometimes, folks come back, tired and discouraged by mysterious side effects or bad test results. In health, trust comes from transparency. Full data, disclosure, and supervision are the foundation for safety.
No one has mapped out how this molecule moves through the human body—how quickly it breaks down, which organs process it, or if it leaves lasting changes in hormone levels. Researchers haven’t nailed down effective doses or flagged dangerous levels. Even studying related drugs doesn’t fill in all those blanks. Nobody has hard data about how this compound interacts with common medications or existing medical conditions.
Major health agencies haven’t signed off on this chemical. If a doctor mentions it at all, it’s probably in an academic setting, not in a patient exam. Agencies like the FDA or the European Medicines Agency run long safety trials for a reason—they demand solid proof before products land on pharmacy shelves. This compound hasn’t cleared those hurdles. No one checks illegal supplements for purity, so anyone ordering mysterious powders online gambles with their health.
People looking for an edge sometimes lose sight of the basics. If something hasn’t made it through proper studies, that’s a red flag. Talk to a healthcare provider before even thinking about new supplements or experimental drugs. Side effects that seem minor can pile up over time, leading to bigger problems that no website ad or social media post ever warns you about. The best path involves patience, trusted advice, and caution around unproven compounds—especially ones as unexplored as 4-Aza-5Alpha-Androsta-1-En-3-One-17Beta-Carboxylic Acid.
Every popular product on the market comes with excitement—and with questions. New health supplements, skincare creams, or tech wearables attract attention. Friends share recommendations, advertisements splash big promises, and sometimes it feels like everyone is eager to give something a try. But stories thrive on both success and struggle. Every enthusiastic testimonial has a counterpart: the side effects someone quietly deals with, or the warning buried in the fine print.
Ignoring side effects doesn’t erase them. I remember trying an over-the-counter supplement that promised more energy. Instead, I spent a sleepless night, jittery and puzzled. I searched quickly online and realized that hundreds of people had the same reaction. Only a tiny warning appeared on the bottle, nearly lost among flashy claims. This experience taught me to dig deeper. Every claim deserves a second look—and that’s true for any product.
A lot of consumers only notice side effects once they hit home. It’s easy to trust official packaging or online reviews. But official warnings, supplied by companies or regulators, often use dense language. The challenge: adverse reactions can show up even if a product wins awards or seems totally safe. Short-term discomfort sometimes morphs into long-term problems. This pattern shows up with everything from food additives to wireless earbuds causing ear irritation.
Let’s break down some recurring issues people face. Dietary supplements often trigger digestive upsets—cramps, bloating, or nausea—especially when they add strong active ingredients or chemical fillers. People with allergies run higher risks, and these don’t always appear in bold on packaging.
Skincare products offer radiant skin in commercials, but some cause redness, pimples, or worse when used on sensitive skin. For every person who glows, someone struggles with a breakout. Personal gadgets place similar stress on the body—think wristbands causing rashes or wireless headphones sparking mild headaches after long wear. If you already manage a health condition, every new variable adds a layer of unpredictability.
Statistics from the FDA and consumer advocacy groups point out that a notable percentage of product recalls come from unanticipated side effects. In 2022, the FDA recorded over a thousand medical device incidents related to skin irritation and allergic reactions. The supplement market experiences similar problems—especially among products sold online, outside regulatory control.
Doctors and pharmacists see these situations every week. The Mayo Clinic reports that unsupervised use of herbal supplements is one of the top causes of unexplained symptoms among their patients. Scientific journals report that nearly twenty percent of consumers encounter mild to moderate side effects with over-the-counter health products.
With so many excitement-driven purchases today, a grounded approach works best. Before buying, check more than just star ratings. Look for clinical studies—not just testimonials. Talk with healthcare pros if you’re unsure. Report your side effects, even small ones. That helps create a clearer safety record for others.
Choose trusted brands—those that publish test results and accept public scrutiny. Stay alert for new warnings as more people share their stories. Remember, staying informed is an active process, not a one-time check. Every question asked helps improve safety for the next person standing in front of a crowded shelf.
Anyone who’s spent time around research labs knows that a compound like 4-Aza-5Alpha-Androsta-1-En-3-One-17Beta-Carboxylic Acid doesn’t play by simple rules. Some chemicals tolerate sunlight, careless hands, and wide temperature swings. This one calls for a bit of respect. Charged with delicate bonds and a structure that can easily shift, improper storage means rapid breakdown and wasted time. I’ve learned—sometimes the hard way—that shelf life shrinks fast unless you handle each powder or solution with the right habits.
Research and long conversations with colleagues back up one thing: room temperature storage invites problems. Lab experience shows cold temperatures slow the slow drift toward deterioration. Most researchers who’ve handled this compound keep it in refrigerators or dedicated cold storage, usually at 2–8°C. Not every fridge has the same humidity control—so containers must keep out moisture.
Letting light hit this compound for long periods risks changing its structure. I always reach for amber vials, the same kind used for a lot of sensitive pharmaceuticals. These block most light and keep the powder’s chemistry stable. Simple, but effective. Lab routines go smoother when every container gets labeled with the date received and the batch. That gives you a fighting chance to know what’s fresh.
Every lab stocks dozens of storage vials, but not all of them seal well. Thin plastic lids leak air—not the best option. Screw-cap glass or PTFE-lined vials keep the air out and the compound in. I’ve skipped plastic for long-term storage ever since I found moisture inside one batch just weeks after opening. Extra protection like a desiccant inside the jar absorbs stray moisture.
Keeping the powder away from air includes closing every lid tight, every time. Sounds basic. I’ve seen more than one researcher regret a ten-second rush that ruined hundreds of dollars’ worth of material. In my own work, I use clear visual cues—red tape or “close lid” signs—especially when others help with storage.
Sometimes this compound needs dissolving before it goes into another experiment. After mixing, solutions rarely last as long as the solid. Always mix solutions fresh, or store them just a few days at low temperature—say, in a 4°C fridge. Don’t let the solution come to room temperature and then try to cool it again; temperature cycling encourages decomposition and precipitation.
Reliable tracking saves money and time. Every researcher should keep logs of when each batch was made, how it was stored, and how it performed in assays. Reviewing these notes gave my team early warning on a batch that lost potency in just weeks, prompting us to switch to double-sealed, cold storage with regular checks. Stability isn’t a guessing game; frequent observation and quick reactions protect both research integrity and budgets.
Safety and reliability come from routines—store cold, avoid light, keep containers airtight, use proper labeling, and make storage a shared responsibility. Sticking to these habits keeps both the compound and the research on track. Even one slip can overshadow months of careful work.
Walking into a pharmacy or scrolling online for something to ease allergies or pain can turn tricky fast. Many shelves offer similar-looking items, but a handful sit behind the counter or carry stern warnings. Is a prescription required? To an outsider, this sounds straightforward, but rules aren’t always clear-cut. I’ve seen family and friends, especially older relatives, assume they could get what a doctor once recommended after their refill ran out. The assistant shakes their head, saying, “Sorry, only with a prescription,” and the cycle starts again: scheduling, waiting, driving, all for something familiar.
Prescription rules grew out of lessons—often painful ones—from decades when anyone could walk away with medicine that ended up causing serious harm. Prescription drugs often treat specific conditions or can spark dangerous reactions if combined with the wrong over-the-counter medicine. Many people forget that a simple mistake—like mixing cold medicine with certain antidepressants—can land someone in the hospital. Regulations reflect not just bureaucratic caution but years of hard-learned wisdom. Every pill isn’t just a product; it can mean life or death, especially for kids, seniors, or someone with a rare disease.
Walk through any supermarket and you’ll spot rows of acetaminophen, cough drops, antacids, and supplements. These options are considered safe enough, with clear directions and a low risk of major side effects. Decades of data show that millions use these without ending up in the emergency room. Regulatory agencies, like the FDA, constantly test these products, weighing the risk against the benefit. That’s not to say over-the-counter stuff is harmless—plenty of people ignore labels and take more than suggested, but the odds of disaster drop so long as people keep an eye on dosage and watch for obvious warnings.
A strong trust link connects patients to pharmacists and doctors. I’ve worked with people who saw prescriptions as red tape, but doctors spot allergies, drug interactions, and hidden symptoms that most people miss. A cough syrup might look harmless, but for someone on blood pressure medicine, it can cause spikes or other trouble. Sometimes, the frustration comes from legitimate barriers—appointments are hard to get, doctors are swamped, insurers make mistakes. These obstacles feed a temptation to shop elsewhere or click on risky websites promising easy access for cash.
Clearer communication can make this process less of a guessing game. Pharmacies should flag items needing a prescription without the legal jargon. Websites and packaging ought to offer plain language and visible warnings. Too many people learn the rules only after a surprise or a confrontational moment at the register. I’ve watched grandparents frustrated by changing rules and neighbors searching message boards for hacks or cheap alternatives. Open lines with healthcare professionals and well-trained pharmacists make a difference. Extending pharmacy hours, offering telemedicine for fast renewals, and using digital reminders could remove some stress, while still protecting people from avoidable danger.
The rules about prescriptions aren’t just to frustrate customers or protect profits. They come from a long record of learning, sometimes with real suffering behind them. By making information simple to find and relying on professionals who listen and explain—not just enforce—we can protect people without leaving them confused at the pharmacy counter.
| Names | |
| Preferred IUPAC name | (5S,8R,9S,10S,13S,14S)-4-aza-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthrene-3-one-17β-carboxylic acid |
| Pronunciation | /ˈfɔːr ˈæzə faɪvˈæl.fə ænˈdrɒstə wʌn en θri oʊn ˈsɛv.ənˈtiːn ˈbiː.tə kɑːrˈbɒk.sɪl.ɪk ˈæsɪd/ |
| Preferred IUPAC name | 17β-Carboxy-4-aza-5α-androst-1-en-3-one |
| Other names |
Finasteride
MK-906 Proscar Propecia SH-80881 4-azaandrost-1-en-17β-carboxylic acid-3-one |
| Pronunciation | /ˈfɔːr-ˈeɪzə-faɪvˈæl.fə-ænˈdrɒs.tə-wʌn-ˈɛn-θri-oʊn-sev.ənˈtiːn-ˈbiː.tə-kɑːrˈbɒk.sɪl.ɪk ˈæs.ɪd/ |
| Identifiers | |
| CAS Number | 979-02-2 |
| Beilstein Reference | 2791043 |
| ChEBI | CHEBI:35049 |
| ChEMBL | CHEMBL2111397 |
| ChemSpider | 10858744 |
| DrugBank | DB01481 |
| ECHA InfoCard | 05a957bf-6e4b-41cf-a4f2-574f37d5b7bb |
| EC Number | NA |
| Gmelin Reference | 82248 |
| KEGG | C18347 |
| MeSH | D000929 |
| PubChem CID | 71312877 |
| RTECS number | KY9225000 |
| UNII | 1S63R731NZ |
| UN number | Not regulated |
| CAS Number | 979-02-2 |
| Beilstein Reference | 3858732 |
| ChEBI | CHEBI:76327 |
| ChEMBL | CHEMBL503 |
| ChemSpider | 20369217 |
| DrugBank | DB01702 |
| ECHA InfoCard | ECHA InfoCard: 1008982 |
| EC Number | EC Number: 618-187-2 |
| Gmelin Reference | 785709 |
| KEGG | C11297 |
| MeSH | C17H23NO2 |
| PubChem CID | 6918493 |
| RTECS number | UJ4375000 |
| UNII | JNU85M7Y2E |
| UN number | Not regulated |
| Properties | |
| Chemical formula | C19H25NO3 |
| Molar mass | 315.41 g/mol |
| Appearance | White to off-white crystalline powder |
| Odor | Odorless |
| Density | 1.28 g/cm³ |
| Solubility in water | Insoluble in water |
| log P | 2.6 |
| Acidity (pKa) | 4.45 |
| Basicity (pKb) | 3.86 |
| Dipole moment | 4.06 D |
| Chemical formula | C20H25NO3 |
| Molar mass | 317.41 g/mol |
| Appearance | White to off-white powder |
| Odor | Odorless |
| Density | 1.23 g/cm³ |
| Solubility in water | Insoluble in water |
| log P | 1.68 |
| Acidity (pKa) | 4.45 |
| Basicity (pKb) | 12.17 |
| Magnetic susceptibility (χ) | -8.91×10⁻⁶ cm³/mol |
| Dipole moment | 6.14 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 465.3 J·mol⁻¹·K⁻¹ |
| Std enthalpy of combustion (ΔcH⦵298) | -7087.0 kJ/mol |
| Std molar entropy (S⦵298) | 499.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of combustion (ΔcH⦵298) | -6144.6 kJ/mol |
| Pharmacology | |
| ATC code | No ATC code |
| ATC code | D4B3FDJ7R2 |
| Hazards | |
| Main hazards | Harmful if swallowed. Causes serious eye irritation. Causes skin irritation. May cause respiratory irritation. |
| GHS labelling | GHS07, GHS08 |
| Pictograms | GHS07,GHS08 |
| Signal word | Warning |
| Hazard statements | H315, H319, H335 |
| Precautionary statements | P261, P264, P271, P272, P280, P302+P352, P304+P340, P305+P351+P338, P312, P321, P332+P313, P337+P313, P362+P364, P501 |
| NFPA 704 (fire diamond) | NFPA 704: 1-1-0 |
| REL (Recommended) | 0.1 mg/m³ |
| IDLH (Immediate danger) | Not established |
| Main hazards | Suspected of causing cancer. |
| GHS labelling | GHS07, GHS08, Warning |
| Pictograms | GHS07,GHS08 |
| Signal word | Warning |
| Hazard statements | H302, H315, H319, H335 |
| Precautionary statements | P264, P270, P273, P280, P301+P312, P305+P351+P338, P337+P313, P501 |
| NFPA 704 (fire diamond) | 0-0-0 |
| PEL (Permissible) | PEL (Permissible Exposure Limit) information for 4-Aza-5Alpha-Androsta-1-En-3-One-17Beta-Carboxylic Acid is not established. |
| REL (Recommended) | <5 mg> |
| IDLH (Immediate danger) | NIOSH does not list an IDLH for 4-Aza-5Alpha-Androsta-1-En-3-One-17Beta-Carboxylic Acid. |
Providing high-quality chemical products and logistics solutions for global trade partners.
